Phase 2
Completed N=30
Pharmacokinetics, Efficacy and Safety Assessment of T2345 Compared With Active Comparator in Newly Diagnosed Patients With Open-angle Glaucoma or Ocular Hypertension
Source: ClinicalTrials.gov NCT01494753 ↗Enrolled (actual)
30
Serious AEs
1.7%
Results posted
Jan 2015
Primary outcomePrimary: Mean Intra Ocular Pressure (IOP) at 8.00am — 16.6; 16.3; 17; 15.7 mmHg
Summary
The purpose of this study is to assess the pharmacokinetics, efficacy and safety of T2345 versus an active comparator.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Intra Ocular Pressure (IOP) at 8.00am |
16.6; 16.3; 17; 15.7 | — |
Eligibility Criteria
Inclusion Criteria
- Untreated bilateral newly diagnosed patients with primary open angle glaucoma
Exclusion Criteria
- Any ocular hypertension other than chronic open angle glaucoma
Data sourced from ClinicalTrials.gov (NCT01494753). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.